The $SKYE is limitless for Skye Bioscience as they celebrate their recent listing at the Nasdaq Exchange Opening Bell. 🛎️✨

$SKYE is a pharmaceuticals company developing proprietary molecules to treat diseases involving inflammatory, fibrotic and metabolic conditions.…

Welcoming Skye Bioscience to the Nasdaq Exchange Opening Bell. twitter.com/i/broadcasts/1…

After uplisting to the Nasdaq Global Market last week, Skye Bioscience, Inc. will be ringing the Nasdaq bell this Thursday, April 18 at 6:30am PST/9:30am EST! Join us as we mark this exciting milestone in our journey. Stay tuned for the broadcasting link to watch live, coming…

$SKYE has uplisted to the Nasdaq Global Market, a significant step mirroring its fundamental accomplishments, fundamental life science investors, and capital raised in in the last quarters. We now look forward to reporting Phase 2 glaucoma data in Q2 and starting the Phase 2…

$kye has announced that it's entered into a securities purchase agreement for the sale of 4,000,000 shares of its common stock at $10.00 per share to certain investors in a private placement (the 'PIPE') to certain qualified institutional buyers. Gross proceeds from the PIPE are…

We welcome industry leader, Dr. Annalisa Jenkins, MBBS, FRCP, to our Board of Directors. For additional detail, read the full press release here: bit.ly/3Pb7YWr

Today we reported the completed enrollment of our Phase 2a clinical trial of SBI-100 ophthalmic emulsion in glaucoma and ocular hypertension.

For additional details, read the full press release here: bit.ly/3SRzOYL

#skyebioscience #glaucoma #clinicaltrials

This week, we look forward to joining partners and colleagues at the Glaucoma 360 New Horizons Forum, taking place in San Francisco, California. Company’s management will present during the Innovations in Glaucoma Drugs and Drug Delivery session on Friday, February 9, 2024. See…

$SKYE will present at Oppenheimer's Investor Conference Tuesday, February 13, 2024 at 9:40am ET and will also be available for 1x1 meetings. Read the full PR for more details: bit.ly/3SRg499

#skyebioscience #investor

Our CEO @Punit Dhillon participated in an interview with Xtalks Webinars to discuss the therapeutic potential of the #endocannabinoid system, as well as Skye Bioscience’s mission, recent updates and next steps for our Phase 2 clinical development programs. Tune in here!…

Today, we announced a $50.25 million private placement financing, co-led by leading life science investors, which is expected to fund operations into early 2026, including our planned Phase 2 trial assessing nimacimab in combination with a #GLP -1R agonist for patients with…

January is #GlaucomaAwarenessMonth ! #DYK ? Glaucoma is a leading cause of vision loss and blindness in the United States — especially for older adults. Learn more about #glaucoma : nei.nih.gov/learn-about-ey…
#EyeHealthEducation

$Skye Bioscience has received IND clearance for its Phase 2 clinical trial of nimacimab in obesity and chronic kidney disease. This trial will assess the impact of our peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and…

After $SKYE ’s acquisition of a Phase 2-ready peripheral CB1 inhibitor, nimacimab, in August and advancing our assessment of the clinical and commercial landscape, we are announcing our plan to conduct a Phase 2 study in patients with obesity and chronic kidney disease starting…

$SKYE has started a new initiative to potentially realize value from one of its existing therapeutic drugs. We’ve entered into an exclusive license agreement with Tautomer Bioscience, enabling them to develop and commercialize our proprietary THC prodrug, SBI-100, as a novel…

We are proud to announce that today we treated the first patient in our Phase 2 study evaluating the potential of SBI-100 Ophthalmic Emulsion, Skye’s synthetic THC prodrug eyedrop, which converts into tetrahydrocannabinol ('THC') when delivered into the eye and is intended to…

$SKYE will present an overview of its #glaucoma program at two #ophthalmology -focused conferences:

BTIG 3rd Annual Ophthalmology Day
Virtual fireside chat: Monday, November 27, 11:30 AM ET

OIS XIII Ophthalmology Innovation Summit
Live presentation during Innovation Showcase:…

$SKYE is pleased to report successful results from its Phase 1 clinical trial assessing the safety and pharmacokinetics of SBI-100 Ophthalmic Emulsion, being developed for the treatment of glaucoma.

Full PR here: bit.ly/40nVSNO

Data from the Phase 1 clinical trial…